The company focuses on disease-specific 3D protein conformations, which exposes new binding sites (epitopes) not present on the same protein in healthy cells. This allows for highly selective drugs that avoid the toxicity common with targets defined by genetic sequence alone.

Genomics (DNA/RNA) only provides the 'sheet music' for cancer. Functional Precision Medicine acts as the orchestra, testing how live tumor cells respond to drugs in real time. AI serves as the conductor, optimizing the 'performance' for superior outcomes.

Numenos AI found that unifying biological data without traditional borders, such as incorporating mouse data or cancer data for dermatological diseases, surprisingly increases the predictive accuracy of their models. This challenges the siloed approach to traditional research.

Pharmaceutical companies like Pfizer have vast amounts of human genetic data (GWAS hits) linked to diseases but struggle to determine which are viable drug targets. Gordian's high-throughput in vivo screening directly tests the causal effects of hundreds of these targets, rapidly identifying the most promising candidates.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

Genomic data (DNA) provides a static blueprint of potential, not a view of the actual biological activity. True understanding requires measuring the dynamic interactions of molecules and cells within tissues "downstream." Current methods capture only fragmentary slices, missing the full picture.

Traditional methods like crystallography are slow and analyze purified proteins outside their native environment. A-muto's platform uses proteomics and AI to analyze thousands of protein conformations in living disease models, capturing a more accurate picture of disease biology and identifying novel targets.

The first wave of microbiome companies failed because the technology wasn't ready. Now, advanced cloud computing and ML can handle the microbiome's vast complexity. Crucially, metabolomics has matured, allowing analysis of what microbes *do* (function), not just who they are (composition), making the data actionable.

Achieving explainability in AI for drug development isn't about post-hoc analysis. It requires building models from the ground up using inherently interpretable data like RNA sequencing and mutational profiles. When the inputs are explainable, the model's outputs become explainable by design.